A shave biopsy is a common dermatologic procedure where a blade is used to remove a superficial sample of skin tissue, including the epidermis and a portion of the dermis. While it is minimally invasive, it involves breaking the skin's integrity, which creates a risk for bleeding. The nurse's priority before any invasive procedure is to identify and communicate factors that increase the risk of complications, particularly hemorrhage. According to the literature on dermatologic surgery, minor postoperative bleeding is the most common complication, and patients on anticoagulant or antiplatelet medications pose a significantly greater risk for bleeding during and after the procedure [4].
Reporting that the client is currently taking warfarin (Coumadin) at 5 mg daily is the most critical action. Warfarin is a vitamin K antagonist that impairs the synthesis of functional clotting factors II, VII, IX, and X, thereby prolonging the international normalized ratio (INR) and increasing the risk of bleeding. The healthcare provider must be informed to make a clinical decision, which may involve checking a pre-procedure INR, temporarily withholding the medication, or bridging with another agent, depending on the indication for anticoagulation and the risk of thrombosis. The perioperative management of antithrombotic therapy requires a careful balance between preventing thromboembolism and minimizing surgical bleeding [2]. While newer direct oral anticoagulants (DOACs) are increasingly used and have their own adverse reaction profiles, the fundamental principle of managing any anticoagulant before a procedure remains a top safety priority .
Option 1: Client reports mild anxiety about the procedure.
Mild anxiety is a common and expected psychological response to a scheduled biopsy. While the nurse should address this with therapeutic communication and education, it is not a physiological safety risk that requires postponing the procedure or an immediate report to the provider. It is a psychosocial need that the nurse can manage independently.
Option 3: Client has a family history of skin cancer.
A family history of skin cancer is a significant piece of the client's health history and is likely one of the reasons the biopsy is being performed. This information is important for risk assessment and diagnosis but does not pose an immediate safety threat during the procedure itself. It does not alter the procedural technique or the risk of an acute complication like bleeding.
Option 4: Client's vital signs are within normal limits.
Normal vital signs are a positive finding indicating the client is clinically stable for the procedure. This is an expected assessment and does not need to be urgently reported as a concern. It confirms the client's current physiological stability.
The core of this question lies in pre-procedural safety screening. A shave biopsy is a planned, minor surgery. The nursing process requires the nurse to recognize that an active pharmacological coagulopathy, induced by warfarin, directly threatens the primary complication of the procedure: bleeding. Knowledge of a patient's bleeding diathesis or medication-induced coagulopathy preoperatively is of the utmost importance for proper preparation and prevention of hemorrhagic complications [4]. While conditions like calciphylaxis represent complex therapeutic dilemmas with warfarin, the immediate pre-procedural concern for any patient on this medication is the universal risk of bleeding .
Before a shave biopsy or any invasive procedure, the priority is identifying factors that increase bleeding risk. A current anticoagulant such as warfarin must be reported immediately.
The healthcare provider may order a recent INR level. For minor dermatologic procedures, an INR within the therapeutic range (typically 2.0-3.0) is often acceptable, but the decision to withhold or bridge therapy depends on the individual's thromboembolic risk.
Never independently advise a patient to stop warfarin. Abrupt discontinuation can cause a rebound hypercoagulable state, increasing the risk of stroke or thrombosis. The managing provider must direct any medication changes.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.